NeoGenomics在与Natera的专利侵权诉讼中获得简易判决胜利，消除了股票面临的部分诉讼阻力，为股价提供了催化剂，Benchmark分析师Bruce Jackson在研究报告中表示。得益于这一裁决，这家癌症检测公司将能够继续在美国制造、使用、销售和推广其RaDaR ST分子残留疾病检测法。
另一方面，Natera表示正在评估其选择，包括上诉以及通过其他专利进一步执法。NeoGenomics股价大涨24%，而Natera股价基本持平。
NeoGenomics在与Natera的专利侵权诉讼中获得简易判决胜利，消除了股票面临的部分诉讼阻力，为股价提供了催化剂，Benchmark分析师Bruce Jackson在研究报告中表示。得益于这一裁决，这家癌症检测公司将能够继续在美国制造、使用、销售和推广其RaDaR ST分子残留疾病检测法。
另一方面，Natera表示正在评估其选择，包括上诉以及通过其他专利进一步执法。NeoGenomics股价大涨24%，而Natera股价基本持平。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.